22 February 2022 · Transcribing is not the preferred option for medicines administration and the alternatives should be considered before committing to transcribing.
16 March 2021 · This Q&A has been developed with the MHRA and it reflects MHRA guidance on the use of PGDs for medications which have risk minimisation measures (RMM).
9 September 2020 · This Q&A provides advice on the legal considerations required when considering mixing medicines to be supplied or administered under a PGD
22 February 2022 · Consideration needs to be given to the risk factors particularly associated with transcribing in non-acute settings with healthcare input
10 June 2021 · The below summary explains the legislation and guidance on the use of PGDs when a medicine is to be used outside its licence ('off-label')
8 January 2020 · The below summary details the legal position regarding the sale, supply or administration of off-label/ unlicenced products under Schedule 17 of the HMR 2012